NeoGenomics (NEO) Tops Q2 EPS by 1c, Beats on Revenues; Reiterates Guidance

NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $66.1 million versus the consensus estimate of $62.97 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• BMO Capital Starts Lululemon (LULU) at Underperform
• Braze stock tumbles 10% on weak third quarter EPS guidance